NEW YORK, July 30 - Zyomyx said today it has pocketed $27 million in a Series E round of private-equity financing.

Investors included existing group Credit Suisse First Boston Private Equity and newcomers Lilly BioVentures and GE Life Science and Technology Finance.

Zyomyx said the cash will go to help ramp up and launch its human cytokine protein-profiling biochip, due in early 2003.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.